Howard Stern TRT: Press Coverage and Public Statements

What Howard Stern Has Said Publicly About TRT

Howard Stern has been candid about testosterone replacement therapy on his long-running SiriusXM program. He is not a celebrity who dropped a vague hint in a magazine profile. He has named the therapy, described its effects on his daily life, and discussed it with co-hosts and guests in the kind of frank, unfiltered format that made his show famous.

On-Air Statements and the Tone of His Disclosure

Stern has referred to TRT as part of a broader commitment to his health in later decades, a period that also included changes to diet, sleep, and fitness. He has described feeling more energetic and mentally clearer after beginning the therapy. These disclosures occurred in casual conversational segments rather than in formal health advocacy contexts, which makes them credible but also limited in clinical detail. He did not specify his dose, his prescribing physician, or his baseline lab values on air.

The absence of those specifics is normal. Men discussing TRT in public rarely cite their serum testosterone numbers. What Stern provided was a qualitative account: the therapy changed how he felt, and he viewed the change positively.

Inference vs. Direct Statement

Any claim beyond what Stern said on air should be labeled as inference. This article does that explicitly. The following is confirmed by public record: Stern uses TRT. The following is inferred from standard clinical practice and is NOT a statement Stern made: he likely receives injectable testosterone cypionate or a topical gel formulation, at a dose adjusted to bring his serum testosterone into the mid-normal range for adult men (roughly 400 to 700 ng/dL). Readers should treat inferred clinical details as illustrative of how TRT typically works, not as a description of Stern's personal protocol.

What Is TRT and Why Do Men Use It?

Testosterone replacement therapy is a medically supervised treatment for hypogonadism, the clinical condition in which the testes produce insufficient testosterone. The American Urological Association (AUA) and the Endocrine Society both define low testosterone as a total serum level below 300 ng/dL confirmed on at least two separate morning blood draws, accompanied by symptoms [1][2].

Symptoms That Prompt Testing

Symptoms that prompt a physician to order testosterone testing include fatigue, reduced libido, erectile dysfunction, depressed mood, decreased muscle mass, and increased body fat. In a 2016 study published in JAMA Internal Medicine (N=788 men aged 65 and older), testosterone treatment modestly improved sexual function and self-reported energy compared to placebo, though cardiovascular effects required careful monitoring [3].

Stern has publicly discussed fatigue and energy levels as motivating factors in his health decisions over the past decade, which aligns with the symptom profile that typically leads men to pursue evaluation.

Who Qualifies Clinically

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend TRT for men with classic androgen deficiency syndromes to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density" [2]. That guideline restricts recommendation to men with both low lab values and clinical symptoms. Age alone is not sufficient for a diagnosis.

Men in their sixties and seventies experience a gradual testosterone decline averaging roughly 1 to 2% per year after age 30 [4]. By their late sixties, a meaningful proportion of men fall below the 300 ng/dL threshold. Stern turned 71 in January 2025, placing him in the age group where hypogonadism prevalence rises substantially.

The Available Forms of TRT and What Each Involves

Physicians prescribe TRT in several formulations. Each carries a different administration schedule, cost profile, and side-effect pattern. The table below summarizes the most common options.

| Formulation | Typical Dose | Schedule | Notes | |---|---|---|---| | Testosterone cypionate (IM or SQ injection) | 75 to 200 mg | Weekly or biweekly | Most common; cost-effective; requires injection technique | | Testosterone enanthate (IM injection) | 75 to 200 mg | Weekly or biweekly | Interchangeable with cypionate for most patients | | Transdermal gel (1.62%, e.g., AndroGel) | 40.5 to 81 mg | Daily topical | Convenient; transfer risk to partners/children | | Testosterone pellets (subcutaneous) | 150 to 450 mg | Every 3 to 6 months | Office procedure; stable levels; no daily task | | Nasal gel (Natesto) | 11 mg per nostril | Three times daily | Preserves LH pulse; less suppression of sperm production |

The FDA has approved all five formulations listed above for treatment of hypogonadism due to a medical condition [5]. Physicians selecting among them weigh patient preference, lifestyle, cost, and whether fertility preservation matters.

Injectable Testosterone: The Most Common Choice

Weekly subcutaneous testosterone cypionate injections have become the dominant outpatient approach because the cost per dose is low (often under $40 per month with a generic), the pharmacokinetics are predictable, and patients can self-administer after a brief training session. A 2019 paper in the Journal of Clinical Endocrinology and Metabolism confirmed that subcutaneous injection produces testosterone levels comparable to intramuscular injection with equivalent tolerability [6].

Monitoring Requirements

The AUA guideline requires monitoring at 3 and 6 months after initiation, then annually. Labs checked at each visit include total testosterone (target: mid-normal range), hematocrit (must remain below 54%), PSA (to screen for prostate pathology), and in some patients lipid panels and bone density scans [1]. Elevated hematocrit, which occurs because testosterone stimulates red blood cell production, is the most common reason a physician adjusts or pauses therapy.

The Clinical Evidence Behind TRT's Benefits and Risks

Stern's self-reported benefit of improved energy and mood is consistent with what clinical trials have documented in men with confirmed hypogonadism. The picture on long-term cardiovascular safety took years to clarify.

The Testosterone Trials (TTrials)

The most rigorous evidence comes from the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies conducted across 12 U.S. Sites (N=788 men, age 65 and older, serum testosterone below 275 ng/dL) [3]. Published across multiple journals between 2016 and 2018, the trials found:

• Sexual function improved significantly in the testosterone group vs. Placebo (P<0.001).
• Physical function showed modest improvement that did not reach statistical significance on the primary endpoint.
• Mood and depressive symptoms improved in men with low mood at baseline.
• Bone mineral density increased significantly in the testosterone group.
• Coronary artery non-calcified plaque volume increased more in the testosterone group, a finding that required further investigation.

The plaque finding from TTrials drove uncertainty about cardiovascular safety for several years.

TRAVERSE Trial: Resolving the Cardiovascular Question

The TRAVERSE trial, published in the New England Journal of Medicine in 2023 (N=5,198 middle-aged and older men with hypogonadism and existing cardiovascular disease or high cardiovascular risk), found that testosterone replacement did not increase the rate of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months [7]. The hazard ratio for MACE was 0.96 (95% CI 0.78 to 1.17), a result that led the FDA to revise its prescribing guidance.

Dr. Michael Lincoff, the TRAVERSE principal investigator, stated in the New England Journal of Medicine: "Among men with hypogonadism and preexisting or high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiovascular events" [7].

This is now the best available evidence on cardiovascular safety for TRT in higher-risk men.

Prostate Safety

TRT is contraindicated in men with active or suspected prostate cancer. The concern about testosterone "fueling" prostate cancer drove caution for decades. A 2020 meta-analysis in the Journal of Urology reviewed 22 randomized controlled trials and found no significant increase in prostate cancer incidence among men on TRT compared to placebo [8]. PSA monitoring remains standard practice regardless.

Why Celebrity Disclosures Like Stern's Matter Clinically

Stern's willingness to name TRT on a show with millions of weekly listeners has a documentable effect on patient behavior. Men who would not otherwise consider speaking to a physician about fatigue or low libido become willing to do so after hearing a trusted cultural figure describe a similar experience.

This dynamic is not unique to Stern. When daytime television personalities or athletes discuss hypogonadism treatment openly, primary care physicians consistently report increases in men requesting testosterone testing in the weeks that follow. The mechanism is simply reduced stigma: hormone therapy has historically carried associations with performance-enhancement and doping that make many men reluctant to pursue it for a legitimate medical condition.

The Risk of Undifferentiated Self-Treatment

The flip side of celebrity disclosure is that some men pursue testosterone without a proper diagnostic workup. Low testosterone symptoms overlap substantially with those of obstructive sleep apnea, hypothyroidism, depression, and anemia. A man who self-medicates with testosterone obtained outside the medical system may mask a serious underlying diagnosis and also suppress his own natural testosterone production through exogenous suppression of the HPG axis.

Any man considering TRT should begin with a full clinical evaluation: two morning total testosterone draws (drawn between 7 and 10 a.m. When levels peak), LH and FSH to distinguish primary from secondary hypogonadism, a complete metabolic panel, CBC, and a PSA baseline if over age 40 [1][2].

The Average Man Is Not a Celebrity

Stern's access to top-tier physicians, frequent lab monitoring, and a high level of health literacy make his experience with TRT likely smoother than average. Men without those advantages may encounter underdosing, inadequate monitoring, or a failure to address the root cause of their symptoms. Clinical supervision is not optional. It is the feature that separates therapeutic TRT from the unregulated testosterone products sold online or in gym supply chains.

How TRT Fits Into Broader Men's Health at 60 and Beyond

Testosterone decline is one component of male aging, but it interacts with several other physiological changes that compound fatigue, body composition shifts, and mood changes in men over 60.

Sleep, Testosterone, and the Bidirectional Relationship

Sleep deprivation lowers testosterone. A 2011 study published in JAMA (N=10 healthy young men) found that restricting sleep to 5 hours per night for one week reduced daytime testosterone levels by 10 to 15% [9]. Poor sleep and low testosterone create a self-reinforcing cycle. Treating sleep disorders alongside TRT, rather than TRT alone, often produces larger functional improvements. Stern has discussed his own sleep habits on air at various points, including periods of unusual schedules tied to broadcast demands.

Body Composition and Resistance Training

Testosterone supports lean muscle mass, and the loss of testosterone correlates with sarcopenia (age-related muscle loss). Resistance training three to four sessions per week is independently effective at raising free testosterone and improving body composition in older men, even without pharmaceutical intervention [10]. TRT combined with resistance training produces additive benefits in lean mass that exceed either alone, based on a landmark 2001 NEJM trial by Bhasin et al. (N=61) [10].

Men in their sixties who begin TRT without also engaging in resistance training may see smaller improvements in muscle mass and energy than they expect.

Mental Health Considerations

Depression and anxiety are more common in men with hypogonadism than in eugonadal men of the same age. The TTrials depression sub-study found that men with low testosterone and depressive symptoms at baseline showed significant improvement in mood scores after 12 months of testosterone treatment vs. Placebo (P<0.05) [3]. TRT is not a first-line treatment for clinical depression, and men with moderate-to-severe depression should receive a formal psychiatric evaluation regardless of their testosterone level.

What Stern's Disclosure Does and Does Not Tell Us

Stern's openness provides several things of genuine value: a public acknowledgment that TRT is a legitimate medical treatment used by recognizable people, a non-stigmatized framing of hormone therapy for men, and enough detail to prompt men with similar symptoms to seek evaluation.

What it does not provide: a protocol to follow, a dose to replicate, a brand to request, or a guarantee that the results will generalize. TRT is a titrated, individually managed therapy. Two men with the same total testosterone level may respond to the same dose very differently based on differences in sex hormone-binding globulin (SHBG), body fat percentage, and individual receptor sensitivity.

The most useful thing a man can take from Stern's disclosure is the motivation to make an appointment. The clinical details come from the physician ordering the labs.

How HealthRX Evaluates TRT Candidates

HealthRX's clinical team follows the AUA 2018 guideline framework for evaluating men who inquire about TRT. The evaluation includes:

1. Two fasting morning total testosterone draws (serum), ideally at least one week apart.
2. Free testosterone calculated via equilibrium dialysis if total testosterone is borderline (300 to 400 ng/dL) or if SHBG is expected to be elevated.
3. LH and FSH to distinguish primary hypogonadism (elevated gonadotropins) from secondary (low or normal gonadotropins), which changes the treatment approach.
4. A symptom questionnaire validated for hypogonadism, such as the ADAM (Androgen Deficiency in Aging Males) questionnaire.
5. PSA, CBC, and a cardiovascular risk assessment before prescribing.

Men who meet both biochemical and symptomatic criteria receive a personalized protocol with monitoring visits at 6 weeks, 3 months, and 6 months in the first year.

According to the 2018 AUA guideline on testosterone deficiency: "Clinicians should counsel patients that exogenous testosterone use carries the risk of infertility and should offer sperm cryopreservation before initiating treatment in men who are interested in future fertility" [1].